These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2053921)

  • 21. Total and free plasma and total synovial fluid piroxicam concentrations: relationship to antiinflammatory effect in patients with reactive arthritis and other arthritides.
    Hundal O; Kvien TK; Glennås A; Andrup O; Karstensen B; Thoen JE; Rugstad HE
    Scand J Rheumatol; 1993; 22(4):183-7. PubMed ID: 8356411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transsynovial kinetics of lonazolac and its hydroxy metabolite in synovitis patients.
    Deneke J; Luckow V; Guserle R; Pässler HH
    Int J Clin Pharmacol Ther; 1998 Aug; 36(8):418-24. PubMed ID: 9726694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of lumiracoxib in plasma and synovial fluid.
    Scott G; Rordorf C; Reynolds C; Kalbag J; Looby M; Milosavljev S; Weaver M; Huff JP; Ruff DA
    Clin Pharmacokinet; 2004; 43(7):467-78. PubMed ID: 15139795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics.
    Karim A; Noveck R; McMahon FG; Smith M; Crosby S; Adams M; Wilton J
    J Clin Pharmacol; 1997 Apr; 37(4):267-78. PubMed ID: 9115051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disappearance kinetics of solutes from synovial fluid after intra-articular injection.
    Owen SG; Francis HW; Roberts MS
    Br J Clin Pharmacol; 1994 Oct; 38(4):349-55. PubMed ID: 7833225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Piroxicam concentrations in plasma and synovial fluid after a single dose of piroxicam-beta-cyclodextrin.
    Bannwart B; Bertin P; Péhourcq F; Schaeverbeke T; Gillet P; Lefrançois G; Trèves R; Dehais J; Netter P; Gaucher A
    Int J Clin Pharmacol Ther; 2001 Jan; 39(1):33-6. PubMed ID: 11204935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical experience with tenoxicam: a review.
    Bird HA
    Scand J Rheumatol Suppl; 1987; 65():102-6. PubMed ID: 3317799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tenoxicam i.v. in major gynaecological surgery--pharmacokinetic, pain relief and haematological effects.
    Jones RD; Miles W; Prankerd R; Lang C; Chilvers M; Lo SK
    Anaesth Intensive Care; 2000 Oct; 28(5):491-500. PubMed ID: 11094663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical pharmacokinetics of lornoxicam. A short half-life oxicam.
    Skjodt NM; Davies NM
    Clin Pharmacokinet; 1998 Jun; 34(6):421-8. PubMed ID: 9646006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synovial fluid and plasma kinetics of repeat dose sustained action tiaprofenic acid in patients with rheumatoid arthritis.
    Nichol FE; Samanta A; Rose CM
    Drugs; 1988; 35 Suppl 1():46-51. PubMed ID: 3359945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of food and various antacids on the absorption of tenoxicam.
    Day RO; Lam S; Paull P; Wade D
    Br J Clin Pharmacol; 1987 Sep; 24(3):323-8. PubMed ID: 3499163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat.
    Lopez-Bustamante LG; Troconiz JI; Fos D
    J Pharm Pharmacol; 1992 Nov; 44(11):898-901. PubMed ID: 1361533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intranasal delivery of tenoxicam in rat.
    Raghavan CV; Abimon VD
    Int J Pharm; 2001 Jun; 221(1-2):227-9. PubMed ID: 11397584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of concurrent aspirin upon plasma concentrations of tenoxicam.
    Day RO; Paull PD; Lam S; Swanson BR; Williams KM; Wade DN
    Br J Clin Pharmacol; 1988 Oct; 26(4):455-62. PubMed ID: 3190995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations.
    Day RO; Francis H; Vial J; Geisslinger G; Williams KM
    J Rheumatol; 1995 Dec; 22(12):2295-303. PubMed ID: 8835565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioavailability of intramuscularly administered tenoxicam.
    Stebler T; Guentert TW
    Biopharm Drug Dispos; 1993 Aug; 14(6):483-90. PubMed ID: 8218966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid.
    Day RO; McLachlan AJ; Graham GG; Williams KM
    Clin Pharmacokinet; 1999 Mar; 36(3):191-210. PubMed ID: 10223168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-performance liquid chromatographic analysis of piroxicam and tenoxicam in plasma, blood and buffer solution. Application to pharmacokinetic studies in small laboratory animals.
    Troconiz JI; Lopez-Bustamante LG; Fos D
    Arzneimittelforschung; 1993 Jun; 43(6):679-81. PubMed ID: 8352822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tenoxicam and ketoprofen level monitoring with high performance liquid chromatography in patients affected by rheumatoid arthritis.
    Corvetta A; Della Bitta R; Luchetti MM; Pomponio G; Ciuffoletti V
    Clin Exp Rheumatol; 1991; 9(2):143-8. PubMed ID: 2060161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tenoxicam pharmacokinetics in rats: a population model.
    Troconiz IF; Lopez-Bustamante LG; Fos D
    J Pharm Sci; 1995 Dec; 84(12):1482-7. PubMed ID: 8748332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.